本文選題：乳腺癌　切入點(diǎn)：MyD88　出處：《廣西醫(yī)科大學(xué)》2015年碩士論文　論文類(lèi)型：學(xué)位論文

【摘要】：目的：髓樣分化因子88(myeloid differentiation factor-88,MyD88)與腫瘤的發(fā)生、發(fā)展和耐藥等事件密切相關(guān)。本文擬檢測(cè)乳腺癌組織中MyD88的表達(dá),初步探討MyD88在乳腺癌化療療效預(yù)測(cè)中的潛在作用。方法：選擇重慶市腫瘤醫(yī)院2009.6-2013.6期間收治的乳腺浸潤(rùn)性導(dǎo)管癌患者59例,全部經(jīng)病理組織學(xué)確診、接受了4周期的TAC方案新輔助化療；記錄Topo Ⅱ、MDR 1、GST-π和p53的表達(dá)狀況；應(yīng)用免疫組織化學(xué)法檢測(cè)MyD88在乳腺癌組織的表達(dá)；采用病理組織學(xué)、臨床療效和病理緩解(pCR)的標(biāo)準(zhǔn)評(píng)估新輔助化療的療效；分析MyD88表達(dá)與化療療效的關(guān)系,以及MyD88表達(dá)與Topo Ⅱ、MDR1、GST-π和p53基因表達(dá)的關(guān)系。結(jié)果：MyD88表達(dá)于部分乳腺癌患者,陽(yáng)性表達(dá)率47.46%；其表達(dá)狀況與乳腺癌化療后的組織病理學(xué)反應(yīng)相關(guān)(P=0.045),MyD88陽(yáng)性表達(dá)者比陰性表達(dá)者療效差；MyD88的表達(dá)狀況與葸環(huán)類(lèi)耐藥相關(guān)的兩個(gè)基因的表達(dá)相關(guān),乳腺癌組織Topo Ⅱ(P=0.007)和p53(P=0.041)基因表達(dá)相關(guān),提示MyD88可能與藥物耐藥有關(guān)。結(jié)論：MyD88在部分乳腺癌患者中呈陽(yáng)性表達(dá)；MyD88的表達(dá)狀況對(duì)乳腺癌TAC方案新輔助化療的療效具有潛在的預(yù)測(cè)價(jià)值；MyD88可能與TAC方案中的化療藥物耐藥相關(guān)。
[Abstract]:Objective: myeloid differentiation factor 88(myeloid differentiation factor-88 MyD88 is closely related to the occurrence, development and drug resistance of tumor. This study is intended to detect the expression of MyD88 in breast cancer. To explore the potential role of MyD88 in predicting the curative effect of breast cancer chemotherapy. Methods: 59 patients with invasive ductal carcinoma of breast admitted in Chongqing Cancer Hospital from September to June 2013.6 were selected and confirmed by histopathology. Four cycles of neoadjuvant chemotherapy with TAC regimen were performed; the expression of GST- 蟺 and p53 in Topo 鈪，

本文編號(hào)：1648355